차세대 시퀸서 시장 보고서 : 시퀀스 유형, 제품 유형, 기술, 용도, 최종사용자, 지역별(2025-2033년)

The global next-generation sequencing (NGS) market size reached USD 23.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 85.4 Billion by 2033, exhibiting a growth rate (CAGR) of 15.5% during 2025-2033. The market for NGS is expanding rapidly due to ongoing technological advancements, increasing use in clinical applications, escalating demand for bioinformatics tools and data analysis solutions, a rising focus on precision medicine, as well as enhanced research and development efforts.

Next-generation sequencing (NGS) is a parallel sequencing technology that determines the sequence of nucleotides in a section of the deoxyribonucleic acid (DNA). It involves various procedures, such as sequencing by synthesis (SBS) and ion semiconductor, single-molecule real-time (SMRT), and nanopore sequencing. It is a cost-effective solution that assists medical professionals in achieving precise results with high accuracy and speed. It also facilitates research in the fields of clinical diagnostics, personalized and genetic medicines, and agriculture and animal studies. At present, it is utilized in pharmacogenomics to escalate the drug delivery process.

Next-Generation Sequencing (NGS) Market Trends:

The growing global geriatric population and the rising prevalence of various chronic medical disorders, such as cancer, cardiovascular, and neurological disorders, represent one of the key factors positively influencing the market. It can also be attributed to the growing use of genetic maps for guiding scientists to analyze the genes that are responsible for medical conditions. In addition, the widespread adoption of liquid biopsies in cancer diagnostics and the increasing utilization of NGS technologies to introduce non-invasive cancer biomarkers for real-time cancer monitoring and detection are creating a positive market outlook. In line with this, continuous technological innovations in sequencers, such as the integration of cloud-computing systems for enhanced data security and management, are strengthening the market growth. Apart from this, continuous financing by governments of various countries to improve healthcare infrastructure is providing a thrust to the market growth. Furthermore, increasing investments by leading players in research and development (R&D) activities for molecular biology, technical engineering, and sequencing chemistry is offering a favorable market outlook.

Next Generation Sequencing Market Segmentation:

Breakup by Sequencing Type:

Whole Genome Sequencing

Targeted Resequencing

Whole Exome Sequencing

RNA Sequencing

CHIP Sequencing

De Novo Sequencing

Methyl Sequencing

Others

Targeted resequencing represents the largest market segment due to the presence of numerous companies in the NGS market offering targeted resequencing services.

Breakup by Product Type:

Instruments

Reagents and Consumables

Software and Services

Reagents and consumables represent the most commonly used product type that assists in sample preparation, DNA isolation, sample cleanup, target enrichment, and quality assurance.

Breakup by Technology:

Sequencing by Synthesis

Ion Semiconductor Sequencing

Single-Molecule Real-Time Sequencing

Nanopore Sequencing

Others

Sequencing by synthesis finds extensive applications on account of its high accuracy in performing DNA sequencing and its growing incorporation in NGS instrumentation. In addition, it offers the highest yield of error-free throughput results.

Breakup by Application:

Biomarker and Cancer

Drug Discovery and Personalized Medicine

Genetic Screening

Diagnostics

Agriculture and Animal Research

Others

Biomarker and cancer currently dominate the market due to the rising prevalence of cancer and increasing awareness among individuals about the benefits of early diagnosis and treatment.

Breakup by End-User:

Academic Institutes & Research Centers

Hospitals & Clinics

Pharmaceutical & Biotechnology Companies

Others

Academic institutes and research centers account for the majority of the market share due to the increasing application of NGS solutions in research projects.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market due to the availability of a technologically advanced healthcare research framework in the region, coupled with the presence of multiple clinical laboratories that employ NGS to provide genetic testing services.

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.

Key Questions Answered in This Report

• 1. How big is the next generation sequencing (NGS) market?
• 2. What is the expected growth rate of the global next-generation sequencing (NGS) market during 2025-2033?
• 3. What are the key factors driving the global next-generation sequencing (NGS) market?
• 4. What has been the impact of COVID-19 on the global next-generation sequencing (NGS) market?
• 5. What is the breakup of the global next-generation sequencing (NGS) market based on the sequencing type?
• 6. What is the breakup of the global next-generation sequencing (NGS) market based on the product type?
• 7. What is the breakup of the global next-generation sequencing (NGS) market based on technology?
• 8. What is the breakup of the global next-generation sequencing (NGS) market based on the application
• 9. What is the breakup of the global next-generation sequencing (NGS) market based on the end-user?
• 10. What are the key regions in the global next-generation sequencing (NGS) market?
• 11. Who are the key players/companies in the global next-generation sequencing (NGS) market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Next-Generation Sequencing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Sequencing Type

• 6.1 Whole Genome Sequencing
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Targeted Resequencing
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Whole Exome Sequencing
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 RNA Sequencing
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 CHIP Sequencing
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 De Novo Sequencing
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Methyl Sequencing
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Others
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast

7 Market Breakup by Product Type

• 7.1 Instruments
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Reagents and Consumables
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Software and Services
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Technology

• 8.1 Sequencing by Synthesis
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ion Semiconductor Sequencing
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Single-Molecule Real-Time Sequencing
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Nanopore Sequencing
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Application

• 9.1 Biomarker and Cancer
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Drug Discovery and Personalized Medicine
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Genetic Screening
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Diagnostics
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Agriculture and Animal Research
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast
• 9.6 Others
  • 9.6.1 Market Trends
  • 9.6.2 Market Forecast

10 Market Breakup by End-User

• 10.1 Academic Institutes & Research Centers
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Hospitals & Clinics
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Pharmaceutical & Biotechnology Companies
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Agilent Technologies Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Becton Dickinson and Company
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 10x Genomics
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 BGI Group
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
  • 16.3.5 Eurofins Scientific
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 F. Hoffmann-La Roche AG
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
  • 16.3.7 Illumina Inc.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Genewiz
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
  • 16.3.9 Macrogen Inc.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
  • 16.3.10 Oxford Nanopore Technologies
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
    • 16.3.10.4 SWOT Analysis
  • 16.3.11 Pacific Biosciences
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
  • 16.3.12 Perkinelmer Inc.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
    • 16.3.12.3 Financials
    • 16.3.12.4 SWOT Analysis
  • 16.3.13 Thermo Fisher Scientific Inc.
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio
    • 16.3.13.3 Financials
    • 16.3.13.4 SWOT Analysis
  • 16.3.14 Qiagen N.V.
    • 16.3.14.1 Company Overview
    • 16.3.14.2 Product Portfolio
    • 16.3.14.3 Financials
    • 16.3.14.4 SWOT Analysis
  • 16.3.15 Genapsys Inc.
    • 16.3.15.1 Company Overview
    • 16.3.15.2 Product Portfolio